According to new research from Rice University, biological markers responsible for extreme depletion in patients with cancer, are now linked to fatigue in patients with Parkinson's disease.
"Inflammation and fatigue in early untreated Parkinson's disease" will appear in the forthcoming issue of Acta Neurologica Scandinavica. This is one of the first studies linking biomarkers responsible for fatigue in cancer patients and patients with Parkinson's disease.
The researchers examined blood samples from 47 patients with Parkinson's disease, half of whom experienced high levels of fatigue, which is characterized by an inability to participate in the normal course of business and destroy jobs, social and daily life.
Chris Fagundes, Rice assistant professor of psychology and one of the leading authors of the study, said that although Parkinson's disease is not fatal, patients often complain that fatigue is one of the most common and tripping side effects and reduces the quality of life.
"Complaint number 1 among Parkinson's disease - chronic fatigue", - said Fagundes.
Researchers have found that people with Parkinson's disease suffer from fatigue, were elevated levels of receptor antagonists of interleukin-1 (IL-1RA) and inflammatory cell adhesion biomarkers 1 (VCAM-1). Interestingly, the elevated levels of inflammatory markers such as these are also associated with fatigue in patients with cancer.
This is the first time that these biomarkers were associated with fatigue in patients with Parkinson's disease, said Fagundes. His previous studies have focused on the relationship between specific biomarkers and related fatigue, cancer, and he said that this study was a perfect opportunity to take the work out of one area and to help the individual to the population.
"This opportunity arose unexpectedly," - Fagunds said. "I was invited to the symposium with a group of internationally renowned experts on Parkinson's Disease in Chicago. Although I did not have any expertise associated with this disease, I was invited because I had published information about biobennyh mechanisms underlying fatigue of cancer."
"Following the presentation of data related to the fact that we know about fatigue related to cancer, we hypothesized that mechanisms were similar. In collaboration with Karen Herlofson, a doctor who treats patients with Parkinson's disease in Western Europe, we conducted a survey to study fatigue and inflammation in patients with Parkinson's through a grant from Parkinson's Foundation. "
Researchers hope that the discovery will allow health professionals to target specific treatments that can reduce levels of inflammatory biomarkers, and, in turn, improve the quality of life for patients.
"This discovery may help health professionals to develop therapies that target the biological mechanisms underlying fatigue", - said Fagundes. "Focusing on the biological mechanism, and not just what to teach patients how to cope with the symptoms, we could potentially alleviate fatigue in these patients."